Will Pharma End Up Paying For The Infrastructure Bill?
Executive Summary
Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?
You may also be interested in...
The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
A Presidential Punt On Drug Pricing
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.